Can schistosomiasis really be consigned to history without a vaccine?

Vaccine

Volumn 26, Issue 27-28, 2008, Pages 3373-3376

  Bethony, Jeffrey M ^a   Diemert, David J ^b   Oliveira, Sergio Costa ^c   Loukas, Alex ^d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Albert B Sabin Vaccine Institute   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Praziquantel; Schistosoma; Vaccine

Indexed keywords

PRAZIQUANTEL;

DRUG EFFECT; ENDEMIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LETTER; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REINFECTION; SANITATION; SCHISTOSOMA; SCHISTOSOMIASIS; TROPICAL DISEASE;

ANIMALS; ANTIGENS, HELMINTH; HUMANS; SCHISTOSOMA; SCHISTOSOMIASIS; VACCINES, SYNTHETIC;

EID: 44749094854     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.045     Document Type: Letter

References (52)

1. Rabinovich N.R. The renaissance in global health. Trends Parasitol 22 7 (2006) 277
2. King C.H., Dickman K., and Tisch D.J. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365 9470 (2005) 1561-1569
3. Fenwick A. Waterborne infectious diseases-could they be consigned to history?. Science 313 5790 (2006) 1077-1081
4. Hotez P., Ottesen E., Fenwick A., and Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol 582 (2006) 23-33
5. Hotez P.J., Molyneux D.H., Fenwick A., Ottesen E., Ehrlich Sachs S., and Sachs J.D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 3 5 (2006) e102
6. Lammie P.J., Fenwick A., and Utzinger J. A blueprint for success: integration of neglected tropical disease control programmes. Trends Parasitol 22 7 (2006) 313-321
7. Bergquist N.R., Leonardo L.R., and Mitchell G.F. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?. Trends Parasitol 21 3 (2005) 112-117
8. Fulford A.J., Ouma J.H., Kariuki H.C., Thiongo F.W., Klumpp R., Kloos H., et al. Water contact observations in Kenyan communities endemic for schistosomiasis: methodology and patterns of behaviour. Parasitology 113 3 (1996) 223-241
9. Woolhouse M.E., and Hagan P. Seeking the ghost of worms past. Nat Med 5 11 (1999) 1225-1227
10. Fulford A.J., Webster M., Ouma J.H., Kimani G., and Dunne D.W. Puberty and age-related changes in susceptibility to schistosome infection. Parasitol Today 14 1 (1998) 23-26
11. Woolhouse M.E. Patterns in parasite epidemiology: the peak shift. Parasitol Today 14 10 (1998) 428-434
12. Butterworth A.E., Capron M., Cordingley J.S., Dalton P.R., Dunne D.W., Kariuki H.C., et al. Immunity after treatment of human Schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses. Trans R Soc Trop Med Hyg 79 3 (1985) 393-408
13. Butterworth A.E., Dalton P.R., Dunne D.W., Mugambi M., Ouma J.H., Richardson B.A., et al. Immunity after treatment of human schistosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment. Trans R Soc Trop Med Hyg 78 1 (1984) 108-123
14. Butterworth A.E., Dunne D.W., Fulford A.J., Thorne K.J., Gachuhi K., Ouma J.H., et al. Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control. Immunol Invest 21 5 (1992) 391-407
15. Butterworth A.E., Fulford A.J., Dunne D.W., Ouma J.H., and Sturrock R.F. Longitudinal studies on human schistosomiasis. Philos Trans R Soc Lond B Biol Sci 321 1207 (1988) 495-511
16. Wilkins H.A., Blumenthal U.J., Hagan P., Hayes R.J., and Tulloch S. Resistance to reinfection after treatment of urinary schistosomiasis. Trans R Soc Trop Med Hyg 81 1 (1987) 29-35
17. Mutapi F., Burchmore R., Mduluza T., Foucher A., Harcus Y., Nicoll G., et al. Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis 192 6 (2005) 1108-1118
18. Butterworth A.E. Human Immunity to schistosomes: some questions. Parasitol Today 10 (1994) 378-380
19. Gryseels B. Human resistance to Schistosoma infection: age or experience. Parasitol Today 10 (1994) 380-384
20. Stelma F.F., Talla I., Polman K., Niang M., Sturrock R.F., Deelder A.M., et al. Epidemiology of Schistosoma mansoni infection in a recently exposed community in northern Senegal. Am J Trop Med Hyg 49 6 (1993) 701-706
21. Butterworth A.E., Curry A.J., Dunne D.W., Fulford A.J., Kimani G., Kariuki H.C., et al. Immunity and morbidity in human schistosomiasis mansoni. Trop Geogr Med 46 4 (1994) 197-208
22. Fulford A.J.C., Butterworth A.E., Sturrock R.F., and Ouma J.H. Some mathematical and statistical issues in assessing the evidence for acquired immunity in schistosomiasis. In: Isham V., and Medley G. (Eds). Models for infectious human diseases: their structure and relation to data (1995), Cambridge University Press, Cambridge
23. Andrews P. Praziquantel: mechanisms of anti-schistosomal activity. Pharmacol Ther 29 1 (1985) 129-156
24. Fallon P.G., and Doenhoff M.J. Active immunization of mice with Schistosoma mansoni worm membrane antigens enhances efficacy of praziquantel. Parasite Immunol 17 5 (1995) 261-268
25. Grogan J.L., Kremsner P.G., Deelder A.M., and Yazdanbakhsh M. Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection. Eur J Immunol 26 6 (1996) 1365-1370
26. Yazdanbakhsh M. Common features of T cell reactivity in persistent helminth infections: lymphatic filariasis and schistosomiasis. Immunol Lett 65 1-2 (1999) 109-115
27. Grogan J., Rotmans P., Ghoneim H., Deelder A., Yazdanbakhsh M., and Klinkert M.Q. Recognition of Schistosoma mansoni cathepsins B and L by human IgG1 and IgG4 antibodies. Parasite Immunol 19 5 (1997) 215-220
28. Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop 86 2-3 (2003) 161-183
29. Campagne G., Garba A., Barkire H., Vera C., Sidiki A., and Chippaux J.P. Continued ultrasonic follow-up of children infected with Schistosoma haematobium after treatment with praziquantel. Trop Med Int Health 6 1 (2001) 24-30
30. Hatz C.F., Vennervald B.J., Nkulila T., Vounatsou P., Kombe Y., Mayombana C., et al. Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania. Am J Trop Med Hyg 59 5 (1998) 775-781
31. Botros S., Sayed H., Amer N., El-Ghannam M., Bennett J.L., and Day T.A. Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. Int J Parasitol 35 7 (2005) 787-791
32. Doenhoff M.J., Kusel J.R., Coles G.C., and Cioli D. Resistance of Schistosoma mansoni to praziquantel: is there a problem?. Trans R Soc Trop Med Hyg 96 (2002) 465-469
33. Ismail M., Botros S., Metwally A., William S., Farghally A., Tao L.F., et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60 6 (1999) 932-935
34. Ismail M., Metwally A., Farghaly A., Bruce J., Tao L.F., and Bennett J.L. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55 2 (1996) 214-218
35. Danso-Appiah A., and De Vlas S.J. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 18 3 (2002) 125-129
36. Hagan P., Appleton C.C., Coles G.C., Kusel J.R., and Tchuem-Tchuente L.A. Schistosomiasis control: keep taking the tablets. Trends Parasitol 20 2 (2004) 92-97
37. Utzinger J., Xiao S.H., Tanner M., and Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8 2 (2007) 105-116
38. Capron A., Riveau G., Capron M., and Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 21 3 (2005) 143-149
39. McManus D.P., and Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 21 1 (2008) 225-242
40. Cook R.M., Carvalho-Queiroz C., Wilding G., and LoVerde P.T. Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage. Infect Immun 72 10 (2004) 6112-6124
41. Zhang D.M., Pan W.Q., Qian L., Duke M., Shen L.H., and McManus D.P. Investigation of recombinant Schistosoma japonicum paramyosin fragments for immunogenicity and vaccine efficacy in mice. Parasite Immunol 28 3 (2006) 77-84
42. Tendler M., Brito C.A., Vilar M.M., Serra-Freire N., Diogo C.M., Almeida M.S., et al. A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine. Proc Natl Acad Sci USA 93 1 (1996) 269-273
43. Siddiqui A.A., Phillips T., Charest H., Podesta R.B., Quinlin M.L., Pinkston J.R., et al. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 21 21-22 (2003) 2882-2889
44. Verity C.K., McManus D.P., and Brindley P.J. Vaccine efficacy of recombinant cathepsin D aspartic protease from Schistosoma japonicum. Parasite Immunol 23 3 (2001) 153-162
45. Da'dara A.A., Skelly P.J., Wang M.M., and Harn D.A. Immunization with plasmid DNA encoding the integral membrane protein, Sm23, elicits a protective immune response against schistosome infection in mice. Vaccine 20 3-4 (2001) 359-369
46. Braschi S., and Wilson R.A. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 5 2 (2006) 347-356
47. Wilson R.A., Ashton P.D., Braschi S., Dillon G.P., Berriman M., and Ivens A. 'Oming in on schistosomes: prospects and limitations for post-genomics. Trends Parasitol 23 1 (2007) 14-20
48. Tran M.H., Pearson M.S., Bethony J.M., Smyth D.J., Jones M.K., Duke M., et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 12 7 (2006) 835-840
49. Cardoso F.C., Pacifico R.N., Mortara R.A., and Oliveira S.C. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol 144 3 (2006) 382-391
50. Hotez P.J., and Ferris M.T. The antipoverty vaccines. Vaccine 24 31-32 (2006) 5787-5799
51. Singer B.H., and Ryff C.D. Neglected tropical diseases, neglected data sources, and neglected issues. PLoS Negl Trop Dis 1 2 (2007) e104
52. Abdulla M.H., Lim K.C., Sajid M., McKerrow J.H., and Caffrey C.R. Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med 4 1 (2007) e14